The effect of continuous versus intermittent delivery of enteral feeding on glycaemic control and gastrointestinal response in critically ill patients (CGM-ICU)

Not Applicable

Completed

• Conditions: Critical Illness; Diet and Nutrition - Other diet and nutrition disorders

• Registration Number: ACTRN12620000917932
• Lead Sponsor: Royal Adelaide Hospital.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-17
• Study Completion: 2022-03-16
• Last Update Posted: 16 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

1.Adults (greater than or equal to 18 years)
2.Admitted to Royal Adelaide Hospital (RAH) ICU
3.Receiving or eligible to receive gastric enteral nutrition
4.Expected to be receiving enteral nutrition in ICU until at least the day after tomorrow.
5.Mechanically ventilated
6. Gastrokinetic medications will be held during the study as appropriate in consultation
with treating clinician

Additional inclusion into the sub-study (day 1) (Subset of 20 patients):
1.Expected to be ventilated for >48 hours (At day -1)
2.Expected to be receiving enteral nutrition for >48 hours (At day -1)

Exclusion Criteria

1.Treating clinician considers intermittent feeding to be clinically contraindicated (continuous feeding is current practice in the RAH ICU)
2.Death is deemed to be imminent or inevitable during admission and the attending doctor, patient, or substitute decision maker is not committed to active treatment.
3.Diagnosed Diabetes Mellitus (type 1 and type 2)
4.Pregnancy
5.Receiving dialysis

Additional exclusion into sub-study (day 1) (Subset of 20 patients):
1.Gastrointestinal surgery on this admission
2.Previous upper gastrointestinal surgery (oesophageal, stomach or duodenal)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glycaemic variability (coefficient of variation of glucose concentrations in mmol/L measured by Continuous Glucose Monitoring).[Over 24 hours (study day 0).];Glycaemic variability (mean and standard deviation of glucose concentrations in mmol/L) measured by Continuous Glucose Monitoring.[Over 24 hours (study day 0).]